A study found that reducing the dose of pembrolizumab in patients with advanced stage non–small cell lung cancer did not ...

One of your patients might be eligible to enroll in a clinical trial currently recruiting people with breast cancer.

1 The trial (NCT05499390) included patients with previously untreated, PD-L1 positive, stage IIIB-IV NSCLC. The patients received the PD-1/VEGF bispecific antibody ivonescimab (n=198) or pembrolizumab ...

Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, "Astellas") will highlight new data from across its approved and investigational cancer therapies during the 2024 European Society ...

Ivonescimab improved PFS when compared to pembrolizumab as first-line therapy in patients with advanced NSCLC in the phase 3 HARMONi-2 trial.

ChromaDex Corp. , the global authority on nicotinamide adenine dinucleotide (NAD+) research with a focus on healthy aging, is excited to announce the second wave of intravenous (IV) wellness clinics ...

The therapeutic landscape for non–small cell lung cancer (NSCLC) has been relatively stable since the 2016 approval of ...

VEGF bi-specific immunotherapy agent showed a clinically significant progression-free survival over pembrolizumab in advanced ...

2 Similarly, the combination of lenvatinib (Lenvima) and pembrolizumab (Keytruda) resulted in an ORR of 54% and a median PFS of 17.4 months. 3 “In terms of overall survival [OS], we are also seeing a ...

NICE has recommended belzutifan for some adults with Von Hippel-Lindau disease, in final draft guidance, which could benefit up to 100 people. Looking back over the journey from our humble beginnings ...

(iv) increases in the Company’s borrowing costs as a result of rising inflation, changes in interest rates and other factors; (v) the Company’s ability to pay down, ...